Lumos Pharma
Tuesday, June 04, 2024
Orphan and Rare Disease
Company Presentation Theater 4
Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. The Company was founded and is led by a management team with longstanding experience in rare disease drug development. Lumos Pharma’s lead therapeutic candidate, LUM-201, is a novel, oral growth hormone (GH) secretagogue, seeking to transform the ~$4.7B global GH market from injectable to oral therapy. LUM-201 is currently being evaluated in multiple Phase 2 clinical studies in Pediatric Growth Hormone Deficiency (PGHD) and has received Orphan Drug Designation in both the US and EU
Company Website:
http://www.lumos-pharma.com
Lead Product in Development:
LUM-201, GH Secretagogue for Growth Hormone Disorders
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2
Exchange
NASDAQ
Ticker
LUMO
Company HQ City
Austin
Company HQ State
TX
Company HQ Country
United States
CEO/Top Company Official
Richard Hawkins
Development Phase of Primary Product
Phase II
Primary Speaker
)
)
)
)
)
)
){kind=logo}
){kind=logo}
.png/fit-in/500x500/filters:no_upscale())